First human tests begin for new obesity injection
NCT ID NCT06132841
Summary
This is an early-stage study to check the safety and side effects of a new injectable drug called AZD6234 in people with overweight or obesity. It will involve 104 healthy adults who will receive the drug or a placebo for 6 to 26 weeks while living at a clinic. The main goal is to see how well the drug is tolerated and how the body processes it, while also measuring early effects on body weight.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY PARTICIPANTS are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Research Site
Glendale, California, 91206, United States
-
Research Site
Brooklyn, Maryland, 21225, United States
-
Research Site
Osaka, 532-0003, Japan
Conditions
Explore the condition pages connected to this study.